Biomarkers of efficacy and safety of the academic BCMA-CART ARI0002h for the treatment of refractory multiple myeloma.
Oliver-Caldés A, Español-Rego M, Zabaleta A, Gonzalez-Calle V, Navarro-Velázquez S, Inoges S, López-Díaz de Cerio A, Cabañas V, López-Muñoz N, Rodriguez-Otero P, Reguera-Ortega JL, Moreno DF, Martínez-Cibrian N, López-Corral L, Pérez-Amill L, Martin-Antonio B, Rosinol L, Cid J, Tovar N, Saez-Peñataro J, Lopez-Parra M, Olesti E, Guillen E, Varea S, Rodríguez-Lobato LG, Battram AM, Gonzalez-Perez MS, Sanchez-Salinas A, González-Navarro A, Ortiz-Maldonado V, Delgado J, Prosper F, Juan M, Martinez-Lopez J, Moraleda JM, Mateos MV, Urbano-Ispizua A, Paiva B, Pascal M, Fernández de Larrea C.
Oliver-Caldés A, et al. Among authors: reguera ortega jl.
Clin Cancer Res. 2024 Mar 11. doi: 10.1158/1078-0432.CCR-23-3759. Online ahead of print.
Clin Cancer Res. 2024.
PMID: 38466644